Search Results
-
Post
Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue
...less than 60 days. (2) A “prescription received” is a commercial order for Optune that is received from a physician certified to treat patients with Optune for a patient not...
-
Post
NCCN Guidelines Recommend Tumor Treating Fields as a Standard Treatment Option for Recurrent Glioblastoma
...is appropriate. Optune is a portable, non-invasive anti-mitotic device that delivers TTFields. In patients with recurrent GBM, Optune demonstrated efficacy outcomes comparable to physician’s choice of chemotherapy, including bevacizumab, with...
-
Post
Novocure Reports First Quarter 2019 Financial Results and Provides Company Update
...(2) A “prescription received” is a commercial order for Optune that is received from a physician certified to treat patients with Optune for a patient not previously on Optune. Orders...
-
Post
CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma
Guidelines provide a framework for using the NovoTAL System to optimize Tumor Treating Fields intensity in Optune patients Tumor Treating Fields extend overall survival when combined with maintenance temozolomide in...
-
Post
Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients
...and Welfare (MHLW) approved the use of Optune in patients with recurrent glioblastoma in March 2015. Optune was approved for the treatment of newly diagnosed glioblastoma by the U.S. FDA...
-
Post
Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Interim Analysis
Data demonstrate superior two, three and four year survival of patients treated with Optune™ together with temozolomide Martin Romero Sanchez of Houston, Texas, is an Optune patient. Download Full Size...
-
Post
Novocure Receives IDE Approval to Initiate METIS Trial
...In the United States, Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). In the United States, Optune with...
-
Post
Red Journal Publishes Data Supporting Personalized Treatment Planning to Increase TTFields Efficacy for Patients with Glioblastoma
...anatomic location of the tumor. The full study can be accessed here. Novocure offers a transducer array layout system, the NovoTAL System, allowing certified Optune prescribers to optimize TTFields therapy...
-
Post
Novocure Announces Data Presentations at the ESMO 2017 Congress
...Optune under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.optune.com/safety or by calling toll free 1-855-281-9301 in the US...
-
Post
Novocure Enrolls First Patient in Phase 3 Pivotal Brain Metastases Trial
...In the United States, Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). In the United States, Optune with...